Intravesical chitosan/interleukin-12 immunotherapy induces tumor-specific systemic immunity against murine bladder cancer

Cancer Immunology, Immunotherapy : CII
Sean G SmithDavid A Zaharoff

Abstract

Bladder cancer is a highly recurrent disease in need of novel, durable treatment strategies. This study assessed the ability of an intravesical immunotherapy composed of a coformulation of the biopolymer chitosan with interleukin-12 (CS/IL-12) to induce systemic adaptive tumor-specific immunity. Intravesical CS/IL-12 immunotherapy was used to treat established orthotopic MB49 and MBT-2 bladder tumors. All mice receiving intravesical CS/IL-12 immunotherapy experienced high cure rates of orthotopic disease. To investigate the durability and extent of the resultant adaptive immune response, cured mice were rechallenged both locally (intravesically) and distally. Cured mice rejected 100 % of intravesical tumor rechallenges and 50-100 % of distant subcutaneous rechallenges in a tumor-specific manner. The ability of splenocytes from cured mice to lyse targets in a tumor-specific manner was assessed in vitro, revealing that lytic activity of splenocytes from cured mice was robust and tumor specific. Protective immunity was durable, lasting for at least 18 months after immunotherapy. In an advanced bladder cancer model, intravesical CS/IL-12 immunotherapy controlled simultaneous orthotopic and subcutaneous tumors in 70 % of treated mic...Continue Reading

References

Oct 2, 1998·Pharmaceutical Research·L Illum
May 21, 1999·Lancet·A B AlexandroffK James
Mar 20, 2002·Cytokine & Growth Factor Reviews·Mario P Colombo, Giorgio Trinchieri
Feb 4, 2003·Nature Reviews. Immunology·Giorgio Trinchieri
Apr 17, 2003·Journal of the National Cancer Institute·Deborah SchragColin B Begg
Jul 26, 2005·Urology·Minoru HorinagaWilliam Larchian
Oct 4, 2005·Laboratory Animals·A LoskogT H Tötterman
Jan 16, 2007·The Journal of Urology·Harry W HerrDean F Bajorin
Aug 19, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michele Del VecchioAndrea Anichini
Oct 27, 2007·Expert Opinion on Biological Therapy·Jonathan M WeissRobert H Wiltrout
Dec 6, 2008·Scandinavian Journal of Urology and Nephrology. Supplementum·D Maxwell Parkin
Feb 17, 2009·World Journal of Urology·Martine PloegLambertus A Kiemeney
Jun 13, 2009·Lancet·Donald S KaufmanAdam S Feldman
Jul 30, 2009·Cancer Research·David A ZaharoffJohn W Greiner
Jul 1, 1974·Urology·J B DeKernionL Persky
Jul 23, 2011·Cancer·Karim ChamieUNKNOWN Urologic Diseases in America Project
Feb 2, 2012·Therapeutic Advances in Urology·Anastasios Anastasiadis, Theo M de Reijke
Jul 11, 2012·Advances in Urology·Eric J AskelandYi Luo

❮ Previous
Next ❯

Citations

Feb 11, 2016·Immunotherapy·Sean G Smith, David A Zaharoff
May 18, 2016·Marine Drugs·Sruthi RavindranathanDavid A Zaharoff
Aug 9, 2016·Bladder Cancer·Laura Douglass, Mark Schoenberg
Jun 21, 2017·Journal of Translational Medicine·Michele GraciottiLana Kandalaft
Dec 14, 2019·Advanced Materials·Shiran FerberNatalie Artzi
Feb 13, 2016·Oncotarget·Joshua M GammonChristopher M Jewell
May 13, 2020·Cancers·Mikołaj WołącewiczPaulina Niedźwiedzka-Rystwej
Dec 19, 2020·Frontiers in Chemistry·Yury E TsvetkovNikolay E Nifantiev
Nov 13, 2020·Frontiers in Immunology·Khue G NguyenDavid A Zaharoff
Jan 8, 2021·Frontiers in Chemistry·Neelam ThakurParames C Sil

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.